NO20051108L - Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse - Google Patents

Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse

Info

Publication number
NO20051108L
NO20051108L NO20051108A NO20051108A NO20051108L NO 20051108 L NO20051108 L NO 20051108L NO 20051108 A NO20051108 A NO 20051108A NO 20051108 A NO20051108 A NO 20051108A NO 20051108 L NO20051108 L NO 20051108L
Authority
NO
Norway
Prior art keywords
taxanes
binding agent
therapeutic use
cytotoxic agents
agents containing
Prior art date
Application number
NO20051108A
Other languages
English (en)
Norwegian (no)
Inventor
Erkan Balogiu
Michael Miller
Ravi V J Chari
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/369,563 external-priority patent/US7390898B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20051108L publication Critical patent/NO20051108L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20051108A 2002-08-02 2005-03-01 Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse NO20051108L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21011202A 2002-08-02 2002-08-02
US10/369,563 US7390898B2 (en) 2002-08-02 2003-02-21 Cytotoxic agents containing novel potent taxanes and their therapeutic use
PCT/US2003/019558 WO2004013093A2 (en) 2002-08-02 2003-07-14 Cytotoxic agents containing novel potent taxanes and their therapeutic use

Publications (1)

Publication Number Publication Date
NO20051108L true NO20051108L (no) 2005-05-02

Family

ID=31498026

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051108A NO20051108L (no) 2002-08-02 2005-03-01 Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse

Country Status (12)

Country Link
US (2) US7495114B2 (cg-RX-API-DMAC10.html)
EP (1) EP1534674A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005539009A (cg-RX-API-DMAC10.html)
KR (1) KR20050032110A (cg-RX-API-DMAC10.html)
CN (1) CN100522955C (cg-RX-API-DMAC10.html)
AU (1) AU2003247587B2 (cg-RX-API-DMAC10.html)
BR (1) BR0313197A (cg-RX-API-DMAC10.html)
CA (1) CA2494074A1 (cg-RX-API-DMAC10.html)
IL (1) IL166624A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA05001390A (cg-RX-API-DMAC10.html)
NO (1) NO20051108L (cg-RX-API-DMAC10.html)
WO (1) WO2004013093A2 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
JP4833862B2 (ja) * 2004-01-28 2011-12-07 サイトイミューン サイエンシズ インコーポレイテッド 官能化コロイド金属組成物および方法
BRPI0511754A (pt) * 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
EP1688415A1 (en) * 2004-12-07 2006-08-09 Aventis Pharma S.A. Cytotoxic agents comprising new C-2 modified taxanes
EP1669358A1 (en) * 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
CA2616906A1 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
JP2011520769A (ja) * 2007-09-21 2011-07-21 サイトイミューン サイエンシズ インコーポレイテッド ナノ治療コロイド金属組成物および方法
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009062138A1 (en) * 2007-11-08 2009-05-14 Virginia Tech Intellectual Properties, Inc. Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
SI2675480T1 (sl) * 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015096553A1 (zh) * 2013-12-24 2015-07-02 于跃 抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
EP3903826B1 (en) 2014-12-04 2024-05-08 Celgene Corporation Biomolecule conjugates
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
EP3778602B1 (en) 2015-07-21 2023-07-12 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3544983A2 (en) 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
RS64961B1 (sr) 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
AU2023313117A1 (en) 2022-07-27 2025-02-13 Mediboston Limited Auristatin derivatives and conjugates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5728725A (en) * 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US6028205A (en) * 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
US5399726A (en) * 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
EP0563475B1 (en) * 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US6339164B1 (en) * 1993-01-29 2002-01-15 Florida State University C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5475011A (en) * 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
WO1996011683A1 (en) * 1994-10-14 1996-04-25 Hauser Chemical Research, Inc. New cytotoxic agents
WO1996023779A1 (en) * 1995-02-02 1996-08-08 Daiichi Pharmaceutical Co., Ltd. Ether derivative
CN1211919A (zh) * 1995-09-13 1999-03-24 佛罗里达州立大学 放射增敏性紫杉烷及其药物制剂
EP0914116B1 (en) 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US5811452A (en) * 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1154782A4 (en) * 1999-02-24 2002-09-25 Uab Research Foundation TAXAN DERIVATIVES FOR TARGETED CANCER THERAPY
HK1049997B (en) * 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6175023B1 (en) * 2000-01-31 2001-01-16 Jian Liu Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III
AU776767B2 (en) * 2000-02-02 2004-09-23 Florida State University Research Foundation, Inc. C10 heterosubstituted acetate taxanes as antitumor agents
HUP0200752A3 (en) * 2000-02-02 2005-02-28 Univ Florida State Res Found C7 carbamoyloxy substituted taxanes as antitumor agents
JP2003522169A (ja) * 2000-02-02 2003-07-22 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのc7ヘテロ置換アセテートタキサン
HK1047934A1 (zh) * 2000-02-02 2003-03-14 佛罗里达州立大学研究基金有限公司 用作抗肿瘤剂的c7碳酸酯取代的紫杉烷
EP1175414A1 (en) * 2000-02-02 2002-01-30 Florida State University Research Foundation, Inc. Taxane formulations having improved solubility
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use

Also Published As

Publication number Publication date
US7414073B2 (en) 2008-08-19
EP1534674A2 (en) 2005-06-01
CA2494074A1 (en) 2004-02-12
US7495114B2 (en) 2009-02-24
WO2004013093A3 (en) 2004-07-01
AU2003247587B2 (en) 2009-07-09
BR0313197A (pt) 2005-08-09
US20050085513A1 (en) 2005-04-21
MXPA05001390A (es) 2005-07-29
WO2004013093A2 (en) 2004-02-12
US20050026997A1 (en) 2005-02-03
JP2005539009A (ja) 2005-12-22
AU2003247587A1 (en) 2004-02-23
EP1534674A4 (en) 2007-11-28
CN100522955C (zh) 2009-08-05
KR20050032110A (ko) 2005-04-06
IL166624A0 (en) 2006-01-15
CN1684948A (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
WO2004013093A3 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
DK1242438T3 (da) Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
KR20030086596A (ko) α,β불포화아릴 술폰을 이용한 이온화 방사선독성으로부터의 세포 및 조직 보호방법
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
DK0923570T3 (da) Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler
UY30736A1 (es) Compuestos quimicos 537
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
GEP20032869B (en) Alpha -Ketoamide Inhibitors of 20S Proteasome, Pharmaceutical Preparations Containing the Same and Methods for Treatment
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
NO20072915L (no) Farmasoytisk preparat som inneholder belagte magnetiske partikler og fremgangsmate for fremstilling av disse, og diagnoseterapisystem
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
PT1506185E (pt) Compostos novos e sua utilizacao
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
WO2005032494A3 (en) Lpa receptor agonists and antagonists and methods of use
AU3850600A (en) Dalda analogs and their use
ATE386725T1 (de) Heterocyclylverbindungen
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen